News from Zyme and the companies we work with.
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology LOUISVILLE, CO and HERCULES, Calif. [...]
Mursla Bio Receives FDA Breakthrough Device Designation for EvoLiver Test
Reflects the potential of EvoLiver test to improve early liver cancer detection among high-risk patients EvoLiver leverages Mursla Bio’s platform based on organ-specific extracellular vesicles circulating in blood Breakthrough status [...]
Atelerix signs exclusive agreement with MineBio to establish distribution channel for non-cryogenic cell preservation solutions in China
Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network Hypothermic preservation technology eliminates costs and inefficiencies of cold-chain logistics to enhance biomedical research [...]
Nuclera expands eProtein Discovery capabilities to enable membrane protein production
Membrane proteins synthesized and purified within 48 hours. Active membrane transporter, MsbA and integral membrane protein, ZMPSTE24 synthesized Cambridge, UK, and Boston MA, USA, 14 April 2025: Nuclera, the biotechnology [...]
Source BioScience acquires Cambridge Clinical Laboratories
Acquisition strengthens clinical diagnostics portfolio, providing a complete offering for preclinical and clinical testing services CCL staff and assets to be based in new clinical lab facilities at Source Genomics [...]
Sphere Bio expands APAC distribution network to strengthen presence in region
Operational scale-up accelerates global growth strategy to increase regional access and technical support Cambridge, UK, 9th April 2025: Sphere Bio, a leading provider of picodroplet-based microfluidics for functional single-cell analysis [...]
IBL International collaborates with Grifols on advanced biomarker panels
Grifols and IBL, a Tecan company, seek to revolutionize clinical diagnostics with a future high-sensitivity, multiplexed immunoassay platform Männedorf, Switzerland, April 8, 2025 – IBL International GmbH, a Tecan company, [...]
Tecan expands portfolio for specialty diagnostics with an asset purchase relating to certain ELISA kits
Männedorf, Switzerland, April 3, 2025 – Tecan Group (SIX Swiss Exchange: TECN) today announced an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS, [...]
BioTrinity 2025: Over 800 Professionals Convene to Paint a Picture of Hope for UK Life Sciences
BioTrinity 2025 welcomed over 800 delegates, matching the highest-ever attendance set in 2024. Three action-packed tracks covered investment trends, regulatory shifts, and cutting-edge scientific advancements. Nearly 10,000 meetings requested, with [...]
4basebio receives MHRA GMP licence for manufacture and supply of synthetic DNA
Cambridge, UK, 02 April 2025 – 4basebio PLC (AIM: 4BB) (“4basebio”), a company which develops and commercialises the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today [...]
Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection
First multiplexed solution introduced with the next-generation Cyto-Mine Chroma platform for more efficient biotherapeutic development Utilizes advanced picodroplet microfluidics technology to integrate analysis of antibody productivity and cell viability of [...]
FairJourney Biologics establishes Supervisory Board
Werner Lanthaler appointed as Chair and joined by global industry leaders The Supervisory Board will define key avenues for growth, accelerate innovation, and optimize scientific strategies to maintain leadership in [...]
